In this episode, our hosts answer listener questions regarding the new ISO 10993-23:2021 from NAMSA’s February 3, 2021 webinar.The standard recommends that In Vitro testing be completed prior to In Vivo testing, warranting many questions about how to deal with legacy data, regulatory acceptance and timelines. Our hosts will provide podcasters a full episode of responses, possible scenarios and potential recommendations.“This is an extraction-based evaluation and you will be creating and dosing extracts in most cases. There is not a direct contact equivalent for the In Vitro like there is In Vivo.” Don Pohl“In the past, you used the intracutaneous or primary skin appropriately, then this In Vitro test is for you.” Don Pohl“We have heard from one Notified Body that they are going to be giving a one-year grace period, [meaning the standard just issued in January 2021], they are giving folks until January 2022 to switch to the In Vitro method.” Sheri Krajewski-Bibins“Similar concept to Part 1, if you already have your data collected, it might be worth mentioning in your biological evaluation report. If you feel like you need to [mention] regarding the timing of events, that testing was already planned, executed and performed prior to -23 issuing, therefore, the In Vivo method was utilized.” Don Pohl“If you are having a pre-sub with the FDA, maybe have that conversation too that you would like to do the In Vitro method, and see what they tell you even though there is no official position.” Sheri Krajewski-Bibins“The standard has the one sentence that says In Vivo may be needed post In Vitro to clarify, but it doesn’t necessarily say because you failed or found an irritant….. I think you need to still be careful on your due diligence. Look at your failure in the In Vitro level, understand the materials, your manufacturing process, and confirm you didn’t miss anything.” Don PohlDiscussion points include:What is in the new 10993-23 and what is it not?How do you know if an In Vitro irritation test is right for an implant?Regulatory agency answers on when they will expect In Vitro irritationLimitations of the In Vitro assayWhat to do if you receive an irritant response in the In Vitro assay

Ver todos los episodios